t******g
发帖数: 462 | 1 不要追高，不过接下来几天如果回调的话是否值得跟进
看不懂产品有多大市场
http://finance.yahoo.com/news/CytoSorbents-Corporation-iw-28021
CytoSorbents Corporation Achieves European Union Regulatory Approval for
CytoSorb(TM)
MONMOUTH JUNCTION, NJ--(Marketwire - 03/31/11) - CytoSorbents Corporation (
OTC.BB:CTSO - News), a critical care focused company using blood
purification to treat life-threatening illnesses, is pleased to announce
that it has achieved European CE Mark approval for its flagship product,
CytoSorb™, as an extracorporeal cytokine filter in situations where
excessive cytokine levels exist. This milestone certifies that CytoSorb&#
8482; has met the safety and label efficacy claim requirements of the
European Medical Devices Directive and can now be sold in the European Union
(E.U.) for human clinical use.
The European Sepsis Trial has successfully demonstrated CytoSorb™'s
robust ability to reduce circulating plasma cytokine levels during the
extracorporeal treatment of critically-ill patients with sepsis and
respiratory failure. CytoSorb™ has achieved its primary endpoint of IL
-6 (interleukin-6) reduction with statistical significance based on an
interim analysis of the trial. The data demonstrates that CytoSorb™
plus standard of care therapy reduced IL-6 levels by an average of 49.1% (p
= 0.01) during the CytoSorb™ treatment period compared to standard of
care therapy alone. The treatment was well-tolerated, with no serious device
related adverse events reported to date in more than 300 treatments in
septic patients.
Dr. Phillip Chan, Chief Executive Officer, stated, "Obtaining European
regulatory approval for CytoSorb™ is the most significant
accomplishment in our company's history and we thank our employees and our
shareholders for their dedication and support. To our knowledge, we are the
only device approved in the E.U. specifically as a cytokine filter, opening
up many opportunities to not just treat patients with sepsis, but also
patients with a host of life-threatening and non-life threatening
inflammatory conditions where cytokine levels are elevated. As we analyze
the clinical data from our current trial in sepsis, we look to continue to
lead and foster additional clinical studies with a strong focus on sepsis
and other critical care illnesses such as acute respiratory distress
syndrome, severe burn injury, trauma, and pancreatitis, where the need is
great and the human and financial costs are staggering. The goal is to drive
broad usage of our technology and generate valuable clinical data across
many fields."
Dr. Chan continued, "Now that we are permitted to manufacture CytoSorb™
; devices for clinical use in the E.U. under CE Mark approval and ISO 13485
certification, we will ramp manufacturing for a controlled-market release in
select territories in the second half of this year. The goal for 2011 is to
build a solid foundation for future growth and responsibly make the
transition from a development stage to a commercial stage medical device
company. Our longer term goal is to pursue trials in the U.S. and attain FDA
regulatory approval as well." Dr. Chan concluded, "With this major
milestone, we continue to advance our mission to change the face of critical
care medicine and to help save patients' lives." | j*****2
发帖数: 306 | 2 this type of play
either chase, or NOTHING...
at CTSO's case, I favor CHASE.
2009 has a report said 10buck if EU approve, now they get it. Also, only
40million market cap.
【在 t******g 的大作中提到】
: 不要追高，不过接下来几天如果回调的话是否值得跟进
: 看不懂产品有多大市场
: http://finance.yahoo.com/news/CytoSorbents-Corporation-iw-28021
: CytoSorbents Corporation Achieves European Union Regulatory Approval for
: CytoSorb(TM)
: MONMOUTH JUNCTION, NJ--(Marketwire - 03/31/11) - CytoSorbents Corporation (
: OTC.BB:CTSO - News), a critical care focused company using blood
: purification to treat life-threatening illnesses, is pleased to announce
: that it has achieved European CE Mark approval for its flagship product,
: CytoSorb™, as an extracorporeal cytokine filter in situations where
| t******g
发帖数: 462 | 3 200９的ｒｅｐｏｒｔ还能找到吗？ 好像不太靠谱，真要能值１０刀，也不会跌到两
毛了。
还有ｏｔｃ的股票，实在看不懂有多少 ｐｏｔｅｎｔｉａｌ ｄｉｌｕｔｉｏｎ，ｔ
ｍｄ，ｆｉｌｅ的什末狗屁１０－Ｑ，先看一阵再说吧，关键还是要看庄家。
Ｆｒｏｍ １０－Ｑ
Liquidity and Capital Resources
Since inception, our operations have been financed through the private
placement of our debt and equity securities. At December 31, 2009 we had
cash of $1,595,628. As of September 30, 2010 we had cash on hand of $758,224
, and current liabilities of $2,037,809.
In October and November 2010 an additional $258,000 was received by the
Company from investors purchasing convertible notes. Additionally during
October and November 2010, the Company sold Common Stock per the terms of
the Purchase Agreement with LPC (See Financial Statement Note 4) at an
average price of $0.107 per share of Common for which it received gross
proceeds of approximately $400,000. In October 2010 the Company received
notice of an award for a cash grant of up to $488,958 from the Federal
Qualifying Therapeutic Discovery Project program for two products in the
Company's research pipeline.
We believe that we have sufficient cash to fund our operations into the
first quarter of 2011, following which we will need additional funding
before we can complete our clinical studies and commercialize our products.
The Company has received SEC approval for a registration statement filed for
the funding agreement with Lincoln Park Capital Fund LLC. Subject to
minimum pricing restrictions per the terms of the funding agreement,
Management believes that the Company will be able to receive ongoing funding
per the terms of this purchase agreement (See Note 4 of Financial
Statements) The agreement with Lincoln Park has the potential to
significantly extend the time that we may be able to fund our operations. We
will continue to seek funding for the long term needs of the Company. There
can be no assurance that we will be able to utilize the Lincoln Park
funding agreement, or that additional financing will be available on
acceptable terms or at all. If adequate funds are unavailable, we may have
to suspend, delay or eliminate one or more of our research and development
programs or product launches or marketing efforts or cease operations.
Our Annual Report dated December 31, 2009 was prepared assuming we will
continue as a going concern, and the auditors' report on those financial
statements expresses substantial doubt about our ability to continue as a
going concern.
【在 j*****2 的大作中提到】
: this type of play
: either chase, or NOTHING...
: at CTSO's case, I favor CHASE.
: 2009 has a report said 10buck if EU approve, now they get it. Also, only
: 40million market cap.
| a********h
发帖数: 819 | 4 happens I have played this stock several times since summer 2009.
I sold most Friday with cost 8 cents.
I wouldn't chase here, they have huge amount of preferred shares that can
convert to common shares any time (about potential 300M shares)
so it's not 40M market cap, it's about 140+M market cap if including
preferred (preferred B shares cost 3 cents!)
I mean, at least it's highly risky
【在 j*****2 的大作中提到】
: this type of play
: either chase, or NOTHING...
: at CTSO's case, I favor CHASE.
: 2009 has a report said 10buck if EU approve, now they get it. Also, only
: 40million market cap.
| a********h
发帖数: 819 | 5 also the 2009 report was a shameless pump.
It pumped the stock to 42 cents then crashed. but the important facts were
missing in that report (it didn't mention the preferred shares, and claim
the trial will be done end of 2009, which was a huge lie)
【在 a********h 的大作中提到】
: happens I have played this stock several times since summer 2009.
: I sold most Friday with cost 8 cents.
: I wouldn't chase here, they have huge amount of preferred shares that can
: convert to common shares any time (about potential 300M shares)
: so it's not 40M market cap, it's about 140+M market cap if including
: preferred (preferred B shares cost 3 cents!)
: I mean, at least it's highly risky
| j*****2
发帖数: 306 | 6 all we need is BIOMED to pump again :D
【在 a********h 的大作中提到】
: happens I have played this stock several times since summer 2009.
: I sold most Friday with cost 8 cents.
: I wouldn't chase here, they have huge amount of preferred shares that can
: convert to common shares any time (about potential 300M shares)
: so it's not 40M market cap, it's about 140+M market cap if including
: preferred (preferred B shares cost 3 cents!)
: I mean, at least it's highly risky
| j*****2
发帖数: 306 | 7 read some info in their message board , it is all about their seconary
endpoint, which will release in 4 to 8week, left imagation for pump.
【在 j*****2 的大作中提到】
: all we need is BIOMED to pump again :D
| t******g
发帖数: 462 | 8 Thanks a lot, that's the best dilution analysis on this stock.
Let's see if they will do some more dilution shortly, I might consider buy
lower than their offer price.
【在 a********h 的大作中提到】
: happens I have played this stock several times since summer 2009.
: I sold most Friday with cost 8 cents.
: I wouldn't chase here, they have huge amount of preferred shares that can
: convert to common shares any time (about potential 300M shares)
: so it's not 40M market cap, it's about 140+M market cap if including
: preferred (preferred B shares cost 3 cents!)
: I mean, at least it's highly risky
|
|
